Healthcare and medical technology company Johnson & Johnson (JNJ) has reported first-quarter financial results that beat Wall ...

Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in adults.

A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it liable in a whistleblower lawsuit for illegally promoting the HIV drugs ...

After years of back-and-forth with the FDA over Hetlioz's potential use as a jet lag disorder treatment, Vanda ...

He also trains his eye on the American media itself, noting ways that reporters at times portrayed the FDA’s actions against ...

Johnson & Johnson announced compelling results ... These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap ...

The Dark Secrets of Johnson & Johnson.” Erythropoietin — also known as EPO — is mostly remembered as the drug that cyclist Lance Armstrong dishonestly used to win seven Tours de France.

Bryan Johnson, the anti-aging influencer, halted his Rapamycin regimen after five years due to adverse side effects like ...

Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya (guselkumab), to treat moderately to severely active Crohn's disease ...